Lysyl‐tRNA synthetase (KRS) is released from cancer cells to modulate the inflammatory response, with caspase‐8 cleavage of KRS exposing the KRS PDZ syntenin‐binding domain, enhancing its EV‐loading. Here, KARS1 is linked to cancer.